Hormonal
GLP-1 receptor agonists (semaglutide and tirzepatide) produce highly heterogeneous weight loss outcomes, with 'super responders' achieving >15% body weight loss while 'minimal responders' achieve <5%, driven by distinct pre-treatment clinical phenotypes rather than uniform biological response.
If you are taking a GLP-1 medication like Ozempic or Mounjaro, understand that your weight loss outcome is not guaranteed to be 'super' (>15% loss). Your pre-existing health conditions (like sleep apnea, psoriasis, or fibromyalgia) may predict how well you respond. Focus on the health benefits of even moderate weight loss (5-15%) rather than comparing yourself to 'super responder' statistics, as individual biology plays a massive role in the final result.
These results highlight significant heterogeneity in weight trajectories following sustained exposure to a GLP-1RA therapy and identify factors associated with increased weight loss, likely reflecting a combination of biological, behavioral, and social factors.
Why this rating
Large real-world cohort (N=135,349) with robust statistical matching, though retrospective and observational.
Source
Decoding the hallmarks of GLP-1RA weight-loss super responders
AJ Venkatakrishnan et al. · Biology Methods and Protocols · 2025
DOI 10.1093/biomethods/bpag021
More from this paper
- Pre-treatment clinical phenotypes, specifically the presence or absence of certain comorbidities, are strongly associated with the likelihood of being a 'super responder' to specific GLP-1RA brands.Good
- Tirzepatide (Zepbound/Mounjaro) is associated with a higher proportion of 'super responders' (>15% weight loss) compared to semaglutide (Ozempic/Wegovy) in real-world settings.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →